Alzheimer's & MCI: our clinical on-ramp.
Brain longevity is the mission. Mild cognitive impairment (MCI) and early Alzheimer's disease are the clinical entry point: indications with severe unmet need, validated biomarker endpoints and accelerable regulatory pathways that let a brain-rejuvenation medicine reach patients sooner.
Today's drugs slow decline. None restore the brain.
Mild cognitive impairment is the symptomatic stage between normal aging and dementia, and a large fraction of people with MCI progress to Alzheimer's disease. Recently approved anti-amyloid antibodies can modestly slow decline in early Alzheimer's, but they do not rebuild lost synapses or neurons.
A vast, growing population
Alzheimer's disease and related dementias affect tens of millions worldwide, with MCI affecting many more, a number rising steeply as populations age.
Slowing is not enough
Current standard of care, including anti-amyloid antibodies, aims to slow progression. Patients and families need approaches that protect and restore cognitive function.
Restoration as the goal
L3 Labs targets the regenerative machinery, neurogenesis, synaptic plasticity and neuronal survival, that aging and Alzheimer's strip away.
The fastest credible path from data to patients.
Validated, mechanism-matched endpoints
Early Alzheimer's and MCI come with established cognitive and biomarker endpoints, giving a clear, measurable path to demonstrate effect.
Accelerated regulatory pathways
Regulators now support biomarker-based, accelerated pathways across the early-Alzheimer's continuum, shortening the road from first-in-human data to approval.
A positive readout de-risks everything
A first-in-human signal in MCI or early Alzheimer's de-risks every downstream use of the platform, including healthy-brain aging and longevity.
From clinic back to longevity
The same neurorestorative mechanism that helps an injured, aging brain is the mechanism we believe can extend cognitive healthspan in everyone.
Restorative effects in an aggressive Alzheimer's model.
In addition to rejuvenating the healthy aged brain, the lead program has shown protective effects in the 5xFAD familial-Alzheimer's mouse.
Preclinical findings from cell and mouse studies. The founding work is available as a preprint and has not yet been peer reviewed. No L3 Labs product has been tested in or approved for use in humans.
Grounded in the peer-reviewed literature.
Mild cognitive impairment: Petersen, New England Journal of Medicine, 2011.
5xFAD Alzheimer's model: Oakley et al., Journal of Neuroscience, 2006.
Adult hippocampal neurogenesis in Alzheimer's: Moreno-Jiménez et al., Nature Medicine, 2019.
Neurotrophic factor neuroprotection in Alzheimer's models: Nagahara et al., Nature Medicine, 2009.
Anti-amyloid therapy in early Alzheimer's: van Dyck et al., NEJM, 2023; Sims et al., JAMA, 2023.
A restorative medicine for the early Alzheimer's continuum.
We are entering the clinic through MCI and early Alzheimer's, on the way to brain longevity for everyone.
Start a conversation